FORM 4

obligations may continue. See

Instruction 1(b)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	RSHIP
Section 10. Form 4 or Form 5	

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  YINGLING JONATHAN MICHAEL						2. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [ IDRA ]								all app	olicable) ctor	10%	ssuer Owner (specify
(Last) (First) (Middle) C/O IDERA PHARMACEUTICALS, INC. 505 EAGLEVIEW BLVD., SUITE 212					3. Date of Earliest Transaction (Month/Day/Year) 01/07/2020								X	belov	N) .	below	
(Street) EXTON PA 19341 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date					Execution D		Date, Transaction Code (Instr.			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Secur Benet Owne		ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)			(11301. 4)
Common Stock 01/07/20								S		1,742(1)	D	\$1.78	04(2)		5,358 <sup>(3)</sup>	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
perivative Conversion Date Exception or Exercise (Month/Day/Year) if a		Execut if any	ion Date, Transac Code (li					Expira (Monti	ation D	ate Year)	Amount of Securities Underlying Derivative Security (Instr. and 4)		-		derivative Securities Beneficially Owned Following Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	(Fir RA PHARN GLEVIEW E  PA  (State of Conversion or Exercise Price of Derivative	(First) (CRA PHARMACEUTICALS GLEVIEW BLVD., SUITE 2  PA 1  (State) (Catalogue Conversion or Exercise Price of Derivative Catalogue Conversion Date (Month/Day/Year)	(First) (Middle) RA PHARMACEUTICALS, INC. GLEVIEW BLVD., SUITE 212  PA 19341  (State) (Zip)  Table I - N  Security (Instr. 3)  Stock  Table II  2. Conversion or Exercise Price of Derivative (Month/Day/Year)  Oberivative 3. Transaction Date (Month/Day/Year) (Month	(First) (Middle) RA PHARMACEUTICALS, INC. GLEVIEW BLVD., SUITE 212  PA 19341  (State) (Zip)  Table I - Non-Derivate (Month/Day)  Stock 01/07/2  Table II - Derivate (e.g., picture of Derivative Price of Derivative (Month/Day/Year)  2. (State) 3. Transaction Date (Month/Day/Year)  3. Topical Stock (Month/Day/Year)	ID (First) (Middle)  RA PHARMACEUTICALS, INC.  GLEVIEW BLVD., SUITE 212  A. If  PA 19341  (State) (Zip)  Table I - Non-Derivative  Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  Stock  Table II - Derivative S (e.g., puts, of Derivative of Derivative (Month/Day/Year)  2. (Conversion or Exercise Price of Derivative Month/Day/Year)  3. Transaction Date (Month/Day/Year)  3. Transaction Execution Date, if any (Month/Day/Year)  4. Transaction Date (Month/Day/Year)  3. Deemed Execution Date, if any (Month/Day/Year)	IDERA IDRA ]  (First) (Middle)  RA PHARMACEUTICALS, INC. GLEVIEW BLVD., SUITE 212  A. If Amend  PA 19341  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  2. Transaction Date (Month/Day/Year) (Month/Day/Year)  Stock  Table II - Derivative Security (e.g., puts, calls, fany (Month/Day/Year) (Month/Day/Year)  2. Conversion or Exercise Price of Derivative Price of Derivative (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Transaction Execution Date, if any (Month/Day/Year)  3. Transaction Code (Instr. 8)	IDERA PHA IDRA ]  (First) (Middle)  RA PHARMACEUTICALS, INC. GLEVIEW BLVD., SUITE 212  Table I - Non-Derivative Securitie  Security (Instr. 3)  Table II - Derivative Securities (Month/Day/Year)  Table II - Derivative Securities (e.g., puts, calls, warra  2. Transaction Date (e.g., puts, calls, warra (A) or Exercise Price of Derivative Security (Month/Day/Year)  3. Date of Earlies 01/07/2020  4. If Amendment,  2. Transaction Date (Month/Day/Year)  (e.g., puts, calls, warra (A) or Exercise Price of Derivative Security (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  3. Transaction Code (Instr. Security (In	IDERA PHARN   IDRA	Corestion   Code   Co	Code   V   Code   Conversion or Exercise   Conversion or Exercise   Conversion or Exercise   Conversion or Exercise   Price of Derivative   Conversion or Exercise   Conversion or	ING JONATHAN MICHAEL   IDRA   IDRA   IDRA   IDRA     3. Date of Earliest Transaction (Month/Day/Year)   01/07/2020   4. If Amendment, Date of Original Filed (Month/Day/Year)   19341   2. Transaction Date (Month/Day/Year)   3. Transaction Date (e.g., puts, calls, warrants, options, convertible of Derivative Security   3. Transaction Date (month/Day/Year)   4. Transaction Date (month/Day/Year)   5. Number of Derivative Securities Acquired (A) or Disposed of (D) (mistr. 3, 4 and 5)   4. Transaction Date (month/Day/Year)   5. Number of Derivative Securities Acquired (Month/Day/Year)   6. Date Exercisable and Expiration Date (month/Day/Year)   6. Date Exercisable and Exercisable	Code   Namount   Charaction   Code   Instructive   Code   Namount   Charaction   Code   Instructive   Code   Namount   Code   Charaction   Charact	IDERA PHARMACEUTICALS, INC.   IDRA	Check   Chec	IDERA PHARMACEUTICALS, INC.   IDRA	IDERA PHARMACEUTICALS, INC.   IDRA	IDRA   IDRA

## **Explanation of Responses:**

- 1. Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 4,525 Restricted Stock Units ("RSUs") on January 3, 2020. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- 2. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$1.76 to \$1.82 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. Of the reported shares, 13,575 shares are represented by unvested RSUs.

/s/ Jonathan Yingling 01/10/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.